A NAD⁺ nasal spray is the same compounded NAD⁺ that goes into an injection, put in a metered pump bottle instead of a syringe. Prices run from about $93 to about $249 a month depending on the seller, it needs a prescription almost everywhere it is sold, and no published human study has measured how much of it gets past the inside of your nose.
That last clause is the decision, so the rest of this page is what sits underneath it: what you are buying, how it is dosed, why the nose is a more reasonable idea than it first sounds, and the four questions worth asking a seller before you pay. Who currently sells one, and for how much, is on our NAD⁺ nasal spray board.
What you are actually buying
In almost every case: a compounded prescription product. There is no FDA-approved NAD⁺ drug in any form, so a pharmacy makes the spray to order against a prescription. Compounded drugs are not FDA-approved and are not reviewed by the FDA for safety, efficacy or quality before they are dispensed. Some sellers say this plainly on the injection page and then describe the identical molecule as a “wellness therapy” on the spray page — Trava Health does exactly that, which is worth noticing, because two pages selling one compound should not disclose it two ways.
The practical differences from a vial and a needle are small and real. No sharps, no injection technique, no bruising. One seller states that its spray requires refrigeration and has to ship two-day or overnight, which is the kind of handling detail that quietly matters if you travel. And the pump itself is a metering device: it delivers a fixed spray volume per actuation, so the schedule on the label — how many sprays, in which nostril, how many times a day — is doing as much work as the concentration in the bottle.
How it is dosed, and why the number is usually missing
Most sellers publish a monthly price and no milligram figure at all, which makes the price uncomparable with anything. A few do publish one, and the published figures do not agree with each other. Trava Health lists a single 100 mg option for both its injection and its spray. Tablet Health’s own checkout data names a 900 mg nasal spray against a 1000 mg injection. Those are two sellers, roughly one order of magnitude apart, describing the same product category.
A strength is also not a protocol. A bottle labeled 100 mg tells you nothing about how many sprays a day, for how many days, or how much of the bottle you are meant to have used by the end of the month. Where a seller states a strength and stops, you know what is in the bottle and not what you are supposed to do with it — and you certainly do not know what reaches your blood, which is the next problem.
Is the nose a plausible route for a molecule like this?
More plausible than most of the skepticism about it assumes, and this is the part that gets argued badly on both sides.
The case against a topical NAD⁺ product is largely about size: skin resists molecules much above about 500 daltons, and NAD⁺ is around 663. The nasal mucosa is not that barrier. A retrospective analysis of intranasally delivered peptides built from the published pharmaceutical record found that peptides with molecular weights up to 6,000 Da have been delivered intranasally — roughly ten times the weight of NAD⁺ — and concluded that high solubility makes it possible to fit useful amounts into the limited volume a nasal spray allows [1]. Desmopressin and calcitonin-salmon are both on the US market as metered nasal sprays. The nose is a working systemic route.
So the honest objection is not that it cannot work. It is that the same analysis names what decides whether a given molecule works this way: permeation enhancers, mucoadhesives, formulation type, pH, osmolality and where in the nasal cavity the spray lands [1]. Those are formulation choices. Not one compounded NAD⁺ spray we have read publishes any of them. You are being asked to assume that a pharmacy solved a delivery problem it has not said it was working on.
What has actually been tested, and in whom
Intranasal NAD⁺ is not an untouched idea in the literature. It has been studied — in animals.
A 2015 study delivered NAD⁺ into the brains of mice to counter neuronal death from misfolded prion protein. Intracerebral injection prevented hippocampal degeneration dose-dependently, and separately, intranasal NAD⁺ in prion-infected sick mice significantly improved activity and delayed motor impairment [2].
The nearer miss is a 2026 study of olfactory loss, a condition its authors open by noting has no established treatment. Mice whose olfactory epithelium had been destroyed with zinc sulfate received intranasal NAD, intraperitoneal dexamethasone or saline; the NAD group recovered olfactory function significantly and its epithelium repaired markedly, and RNA sequencing and in situ hybridization traced the effect to a set of neuronal genes restored in the treated animals [3].
Read what those are. Both are mouse studies with a local target — the brain by way of the olfactory route in one, the nasal lining itself in the other. Neither measured blood NAD⁺ in a person. Neither was testing the energy, focus or anti-aging outcomes a telehealth spray is sold on. They are a good reason for someone to run a human trial. They are not a substitute for one, and a seller quoting them at you is changing the subject.
What we searched for a human study, and when
An absence is only worth stating if you say where you looked, so: on September 13, 2026 we ran four PubMed queries.
Nicotinamide adenine dinucleotide or NAD⁺ in the title or abstract, combined with intranasal or nasal spray, restricted to the human MeSH tag, returned eight records — the mouse anosmia study above, two 2025–2026 neurodegeneration papers using other agents, a murine allergy study, two older NAD⁺ review articles, a paper on oxytocin and CD38, and a bacterial NAD salvage study. None is a trial of intranasal NAD⁺ in people. The same terms combined with the randomized controlled trial and clinical trial publication types returned zero. An all-fields search for the phrases “NAD nasal spray”, “NAD+ nasal spray” and “intranasal NAD+” returned zero. A broader all-fields search for intranasal NAD⁺ returned 37 records, none of them a human trial of the spray.
Run alongside those as a known-good control, a search for intranasal esketamine limited to randomized controlled trials returned 49 records on the same day — so PubMed was answering normally and the query shape works. The empty result is the finding, not a failed search.
The wider context is the same shape. A PRISMA-guided systematic review published in 2026 screened human and rodent intervention studies of NAD-related compounds from January 2010 to October 2025 and identified 113 eligible studies, 33 of them human intervention studies. Its finding on non-oral NAD⁺ is blunt: no eligible outcomes trial evaluated intravenous or intramuscular NAD⁺ itself for anti-aging or wellness indications [4]. If the route that indisputably puts NAD⁺ into your bloodstream has no outcomes trial, the route that has not been shown to put it there is not going to have one either.
The prices say something the biology does not
Line the sellers up and a pattern appears immediately: most of them charge the same for the spray as for the shot. Embody lists $99 a month either way. CoreAge Rx publishes $93 for both. RxSpan MD asks $249 for both. Invyncible shows $192 for both. Tablet Health’s catalog puts both at $149.99. Trava separates them by $1.02.
A handful go the other way and price the spray under the needle. AgelessRx charges $125 a month for the nasal spray against $149 for the injection, and it prices a patch separately again. But identical pricing is the norm, and it tells you how the sellers themselves think about the format: as the same product in a different container, priced on the molecule rather than on any claimed advantage of the route.
That is a reasonable commercial position and a useful one for a buyer, because it makes the route a preference rather than a budget decision. It is also the opposite of what the marketing copy usually implies. A page that charges you injection money for a spray while telling you the spray absorbs better has priced its own claim at zero.
Four questions to ask before you buy
How many milligrams, and how many sprays a day? A strength with no frequency is half a protocol, and a price with no strength cannot be compared with anything.
Does the page say the product is compounded? If the injection page says so and the spray page does not, the spray page is the one being careless.
Is the advertised number the standing monthly rate? Across this category the advertised figure is routinely an intro month, a prepaid quarter divided out, or a coupon the page applies on your behalf. Ask what you pay in month four.
What happens if the prescriber declines? Several sellers take payment before the intake. Find the refund terms before that matters rather than after.
The honest summary
A NAD⁺ nasal spray is a needle-free way to buy compounded NAD⁺ at roughly injection prices from a small number of telehealth sellers. The nasal route itself is credible — it carries larger molecules than this one every day — but nobody has published a measurement showing that a NAD⁺ spray raises NAD⁺ in a person, and the outcomes the category advertises are not established in any format.
If you want the format with randomized human data behind it, that is an oral precursor: a 2 × six-week randomized, double-blind, placebo-controlled crossover trial found chronic nicotinamide riboside well tolerated and effective at stimulating NAD⁺ metabolism in healthy middle-aged and older adults [5], at a fraction of the price. If you want the route whose delivery is at least not in question, that is the injection — and the two are set against each other directly in spray versus injection. If you want the spray because you will not use a needle, buy it for that reason, from a seller who tells you what is in the bottle.